Fig. 5From: A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional statusMean and standard error (SE) for Kidney Disease Quality of life – Short Form-36 (KD-Qol SF-36) questionnaire (values are Z transformed and normalised values for component summary measure of Physical and Mental Health) for IV iron (Ferric Derisomaltose) versus IV placebo at baseline, 1 month and 3 monthsBack to article page